Without a clear picture of which solutions are working and which ones aren’t, it’s difficult for providers to scale AI across their enterprise. As hospitals transition their AI efforts from experimentation mode to the widespread adoption phase, experts agree that more rigorous, real-world evidence is needed.
Many healthcare AI developers lack access to real-world data. To address this, Atropos Health is allowing AI developers to train and deploy their models using its real-world evidence network. The federated healthcare data network consists of more than 300 million patient records gathered from EHRs, claims data and patient registries.
Balancing healthcare benefits and insurance costs requires research. From becoming a Difference Card member to offering wellness resources, there are many ways to improve healthcare at low cost.
Enabling RWD-driven drug development accelerates the approval of more effective and affordable treatments. This approach successfully identifies patient patterns and density indicators and maps causal pathways.
By allowing study teams to design and conduct more inclusive and/or relevant studies, real-world data can enhance the standard of care and ultimately improve patient outcomes.
Miruna Sasu, CEO of RWE company COTA, explained that studies have shown meaningful improvements in efficiency if RWE is used in drug development and that translates into real savings. However, will such efforts continue amidst the ongoing belt-tightening in a tough economy?
A look at how tapping real world evidence from medical devices and patients could be a game changer, improving patient-clinician communication, supporting earlier interventions and helping patients manage their condition.
The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.
For a long time, doctors’ offices, large or small, operated under a seeming contradiction; even as modern medicine pushed the frontiers of innovation, providing new treatments and sometimes cures for devastating diseases, so much of our healthcare system remained stuck in the pre-digital past. The most obvious example is one that many of us have […]
The FDA has expanded emergency authorization of Covid-19 boosters to include children 12 to 15 vaccinated with the Pfizer and BioNTech messenger RNA shot. The decision is based on a study that found boosting reduced deaths by 90%, but that Israeli analysis only evaluated these shots in people 50 and older.
Liberating the genetics, laboratory and pharmacy data that sits deep within healthcare subsystems, while protecting patient information and navigating the global regulatory landscape, is no easy task but would greatly help in the treatment of diseases.
Can an industry coalition help craft policy to support the use of Real-World Evidence? Five prominent real-world data and analytics companies are betting on it, launching the RWE Alliance.
Choosing the right software translates directly into better client management, operational efficiency and growth for your spa franchise. Discover which tool is best for your business.
Patient-generated healthcare data will catalyze a fundamental shift in the way we measure success in medicine – from looking at a series of clinical outcomes viewed through the lens of the healthcare team to considering the entire care experience in partnership with the patient.
Nadine Peters, chief legal officer of COTA, shares her journey to leadership in health data privacy law and policy recommendations for the Biden Administration on achieving health equity through data use and education.
With RWE helping to inform, guide, and refine ongoing protocols and pathways, we can battle Covid-19 and cancer together and be far better prepared in our response to the next pandemic.
The healthcare analytics company said it had raised the extension funding from three new investors and would use it to accelerate development of its real-world evidence technology.
The companies will use a combination of more than seven years of medical record data with five years of prospective data on 5,000 MS patients, including real-world outcomes data and MRI images. Other disease areas to be explored include hematology and rare diseases.